|Bid||149.11 x 1300|
|Ask||149.18 x 800|
|Day's Range||147.93 - 149.41|
|52 Week Range||125.00 - 149.41|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||28.45|
|Earnings Date||Jan 21, 2020|
|Forward Dividend & Yield||3.80 (2.56%)|
|Ex-Dividend Date||Feb 22, 2020|
|1y Target Est||156.63|
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
What happens in the stock market when price acceleration goes vertical and investor complacency reaches extreme levels? Typically, bad things, according to Lance Roberts, chief investment strategist at RIA Advisors.
Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday. Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program.
A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson for allegedly failing to warn men that they could grow breasts by using its antipsychotic drug Risperdal. The decision by Judge Kenneth Powell of the Philadelphia Court of Common Pleas to reduce punitive damages for the plaintiff Nicholas Murray followed a jury's imposition of the original award last Oct. 8. Murray, like other male plaintiffs in mass tort litigation over Risperdal, claimed that he developed breasts after being prescribed the medicine when he was a boy.
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
in a lawsuit related to the antipsychotic drug Risperdal has been cut to $6.8m. in punitive damages to a Maryland man who alleged that J&J failed to properly warn young men that Risperdal could cause enlarged breasts. The plaintiff, Nicholas Murray, was also awarded $680,000 in compensatory damages.
With most blue-chip companies' earnings scheduled over the coming weeks and sentiments being mixed, investors should closely monitor the movement of the Dow ETF.
Wall Street rallied following the first phase of the U.S.-China trade pact, with Dow Jones Industrial Average and S&P 500 closing at record highs.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Concerto HealthAI, founded by a billionaire investor, plans to substantially grow its team and potentially make some acquisitions after raising $150 million.
Yahoo Finance Editor-in-Chief Andy Serwer sits down with Chairman of the Children’s Health Defense, and President of the Waterkeeper Alliance, Robert F. Kennedy, Jr.
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.